These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 6210188

  • 1. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
    Klapdor R, Greten H.
    Dtsch Med Wochenschr; 1984 Dec 14; 109(50):1935-9. PubMed ID: 6210188
    [No Abstract] [Full Text] [Related]

  • 2. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
    Safi F, Büchler M, Schenkluhn B, Beger HG.
    Dtsch Med Wochenschr; 1984 Dec 07; 109(49):1869-73. PubMed ID: 6209082
    [Abstract] [Full Text] [Related]

  • 3. [Ganglioside and carcinoembryonic antigens in the diagnosis of malignant tumors of the gastrointestinal tract].
    Ivanov PK, Samoĭlenko VM.
    Vopr Onkol; 1984 Dec 07; 30(9):55-9. PubMed ID: 6495695
    [Abstract] [Full Text] [Related]

  • 4. [CA-19-9, CA50 and CEA in pancreatic and gastrointestinal tumors. Comparative studies].
    Dienst C, Clodius T, Oldörp T, Uhlenbruck G, Diehl V.
    Med Klin (Munich); 1987 Jan 30; 82(2):45-50. PubMed ID: 3470595
    [No Abstract] [Full Text] [Related]

  • 5. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K, Tasaki N, Miyagawa H, Yoshikawa T, Kondo M.
    Am J Gastroenterol; 1988 Feb 30; 83(2):126-9. PubMed ID: 3422536
    [Abstract] [Full Text] [Related]

  • 6. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon].
    Klapdor R, Klapdor U, Bahlo M, Dallek M, Kremer B, van Ackeren H, Schreiber HW, Greten H.
    Dtsch Med Wochenschr; 1984 Dec 21; 109(51-52):1949-54. PubMed ID: 6595110
    [Abstract] [Full Text] [Related]

  • 7. [Comparison of CA 50 and CA 19-9 tumor markers in benign and malignant diseases of the upper gastrointestinal tract].
    Heptner G, Domschke S, Schneider MU, Siegfried W, Domschke W.
    Dtsch Med Wochenschr; 1986 Mar 07; 111(10):374-8. PubMed ID: 2419074
    [Abstract] [Full Text] [Related]

  • 8. [New monoclonal antibodies in the diagnosis of gastrointestinal cancers].
    Heptner G, Domschke S, Domschke W.
    Internist (Berl); 1986 Nov 07; 27(11):723-8. PubMed ID: 2433247
    [No Abstract] [Full Text] [Related]

  • 9. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
    Czakó L, Takács T, Babarczy E, Dux L, Lonovics J.
    Orv Hetil; 1997 Nov 23; 138(47):2981-5. PubMed ID: 9432648
    [Abstract] [Full Text] [Related]

  • 10. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
    Takami H, Hishinuma S, Shintoku J, Ogata Y, Abe O.
    Gan No Rinsho; 1985 May 23; 31(6 Suppl):631-7. PubMed ID: 3861883
    [Abstract] [Full Text] [Related]

  • 11. Clinical value of CA 19-9 (carbohydrate antigen) in gastrointestinal adenocarcinoma.
    Mennini G, Silecchia G, Zanna C, Cucchiara G, Spadaro G, Greco E, Basoli A, Speranza V.
    Ital J Surg Sci; 1985 May 23; 15(1):37-43. PubMed ID: 3858272
    [Abstract] [Full Text] [Related]

  • 12. [Biohumeral markers in the diagnosis of pancreatic carcinoma].
    Panucci A, Del Favero G, Falmis C, Brosolo P, Basso D, Pedrazzoli S, Baccaglini U, Marchioro L, Bonvilini P, Naccarato R.
    Recenti Prog Med; 1985 May 23; 76(7-8):385-91. PubMed ID: 3865269
    [No Abstract] [Full Text] [Related]

  • 13. Immunologic diagnosis and prognosis of human digestive-tract cancer: carcinoembryonic antigens.
    Zamcheck N, Moore TL, Dhar P, Kupchik H.
    N Engl J Med; 1972 Jan 13; 286(2):83-6. PubMed ID: 4107622
    [No Abstract] [Full Text] [Related]

  • 14. [CA-50: evaluation of a new tumor marker in the diagnosis of neoplastic pathologies of the gastrointestinal tract].
    Pecchio F, Ricci E, Rapellino M, Oliaro A, Adamo MR, Marzola G, Piantino P.
    Minerva Med; 1987 Feb 15; 78(3):141-4. PubMed ID: 3469541
    [Abstract] [Full Text] [Related]

  • 15. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
    Staab HJ.
    Acta Gastroenterol Belg; 1987 Feb 15; 50(1):29-35. PubMed ID: 3480668
    [No Abstract] [Full Text] [Related]

  • 16. [Diagnosis of recurrence and evaluation of the course of pancreatic cancer. Combined use of sonography and the new tumor marker CA 19-9].
    Guthoff A, Klapdor U, Klapdor R, Eichfuss HP, Dallek M, Greten H.
    Dtsch Med Wochenschr; 1984 Sep 14; 109(37):1410-2. PubMed ID: 6383759
    [No Abstract] [Full Text] [Related]

  • 17. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Haglund C.
    Anticancer Res; 2002 Sep 14; 22(4):2311-6. PubMed ID: 12174919
    [Abstract] [Full Text] [Related]

  • 18. [Diagnosis of tumors with the use of immunologic tumor markers].
    Vorlaender KO.
    Wien Med Wochenschr; 1983 Feb 15; 133(3):59-66. PubMed ID: 6189301
    [No Abstract] [Full Text] [Related]

  • 19. [Introduction of a new laboratory marker for cancer of the pancreas (CA 19.9). Current experience].
    Nunes AP, Jukemura J, Machado MC, Scheinberg MA.
    Rev Paul Med; 1986 Feb 15; 104(2):99-101. PubMed ID: 3468583
    [No Abstract] [Full Text] [Related]

  • 20. Immunologic diagnosis of human digestive tract cancer. Carcinoembryonic antigens.
    Kamholz SL.
    Am J Gastroenterol; 1973 Mar 15; 59(3):233-43. PubMed ID: 4121819
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.